Products

Comprehensive product portfolio across APIs, formulations, and biosimilars.

The portfolio includes anti-inflammatory, antifungal, oncology, cardiovascular, neurology, gastroenterology, insulin, and monoclonal antibody programs.

Therapeutic focus

Complex molecules for high-impact categories

KEA Lifescience prioritizes complex generics, oncology molecules, sustained-release systems, biosimilars, and export-ready formulations.

Responsible product communication

Product availability, registration, pack configuration, therapeutic use, and market eligibility should be confirmed with the company team for each jurisdiction.